"The results of the DART study, which showed that patients who did not undergo routine CD4 cell or drug toxicity laboratory monitoring were only marginally more likely to experience disease progression or die while receiving antiretroviral therapy during a five-year study in Zimbabwe and Uganda, were first presented at the International AIDS Society conference in Cape Town in July.
"The study was designed to determine whether antiretroviral therapy could be implemented safely and effectively in a resource-limited setting without routine use of expensive laboratory tests."
Read more in Aidsmap, December 9, 2009.
0 comments:
Post a Comment